Melatonin and sleep disorders associated with intellectual disability: a clinical review.
Melatonin can help clients with ID fall asleep faster, but evidence is thin—use brief low-dose trials and watch the data.
01Research in Context
What this study did
The authors read every paper they could find on melatonin and sleep in people with intellectual disability.
They looked at kids, teens, and adults. They did not run a new experiment. They simply summed up what others had reported.
What they found
Most small studies say melatonin cuts the time it takes to fall asleep.
Total sleep time may grow by 30–60 min.
Yet the studies are tiny and lack control groups, so the proof is weak.
How this fits with other research
Reid et al. (2003) ran a real RCT and saw the same benefit with only 0.3 mg given 30 min before bed.
That trial is the strongest evidence Neuringer et al. (2007) cite, so the two papers agree.
Rzepecka et al. (2011) show poor sleep fuels daytime aggression in kids with ID.
Chu et al. (2009) add that when the child sleeps badly, mom’s mood crashes too.
Together these studies say: fix sleep and you may also cut challenging behaviour and carer stress.
Why it matters
If a client with ID takes over 30 min to fall asleep, ask the doctor about a short melatonin trial. Start low (0.3 mg), give it 30 min before lights-out, and track sleep with a simple log. Stop after a few weeks if nothing changes. Good sleep can trim aggression and give families real relief.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Graph the client’s current sleep-onset time for one week, then ask the MD about a 0.3 mg melatonin test.
02At a glance
03Original abstract
BACKGROUND: Melatonin is used to treat sleep disorders in both children and adults with intellectual disability (ID), although it has no product license for such use. The evidence for its efficacy, potential adverse effects and drug interactions are reviewed in the context of prescribing to people with ID. METHODS: A literature search was performed using multiple electronic databases. More literature was obtained from the reference lists of papers gathered through the searches. RESULTS: Most of the studies were uncontrolled and the few controlled trials available were of small size. Melatonin appears effective in reducing sleep onset latency and is probably effective in improving total sleep time in children and adolescents with ID. It appears to be ineffective in improving night-time awakenings. Melatonin is relatively safe for short-term use. Its safety for long-term use is not established. Potential drug interactions, possible effects on puberty and concerns regarding the use of melatonin in epilepsy, asthma and depressive disorders are discussed. CONCLUSIONS: Melatonin appears to be an effective sleep-initiator for children and adolescents with ID and probably has a similar effect for adults. There may be heterogeneity of response depending on the nature of the sleep problem and cause of the ID or associated disabilities. Further studies are necessary before firm conclusions can be drawn and guidelines for the use of melatonin for people with ID formulated.
Journal of intellectual disability research : JIDR, 2007 · doi:10.1111/j.1365-2788.2006.00893.x